



VERSION 3


MAR 30, 2023

Cell line information V.3

 In 1 collection

Philippa R Kennedy¹, Melissa Khaw¹

¹University of Minnesota



Philippa R Kennedy

University of Minnesota

ABSTRACT

An amalgamation of cell line data in the lab. Its origin and standard culture conditions.

OPEN  ACCESS

DOI:

dx.doi.org/10.17504/protocols.io.rm7vz82o8vx1/v3

Protocol Citation: Philippa R Kennedy, Melissa Khaw 2023. Cell line information.

protocols.io

<https://dx.doi.org/10.17504/protocols.io.rm7vz82o8vx1/v3>

Version created by Philippa R Kennedy

License: This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: In development
We are still developing and optimizing this protocol

Created: Feb 01, 2023

Last Modified: Mar 30, 2023

PROTOCOL integer ID:
76224

Overview

- 1 All cells are maintained in humidified incubators at 37°C, 5% CO₂, unless otherwise specified.

All cells are routinely tested for mycoplasma infection using a PCR-based test (Universal Mycoplasma Detection Kit, ATCC Cat. No. 30-1012K)

Dates of purchase are provided. Aliquots of purchased cells lines are frozen at P0, P1 and P2 from original stocks and P2 are defrosted and used for experimentation as standard.

Cell lines confirmed by short tandem repeat analysis are marked with *.

- 2 Media for cell lines:

R10: RPMI (Gibco Cat. No. 2240-089) + 10% fetal bovine serum (Gibco Cat. No. 26140079) + 100 U/mL Penicillin and Streptomycin (Gibco Cat. No. 15140122)

D10: DMEM (Corning Cat. No. MT10013CV) + 10% fetal bovine serum (Gibco Cat. No. 26140079) + 100 U/mL Penicillin and Streptomycin (Gibco Cat. No. 15140122)

D10-SP (without sodium pyruvate): DMEM (Corning Cat. No. 10-017-CV) + 10% fetal bovine serum (Gibco Cat. No. 26140079) + 100 U/mL Penicillin and Streptomycin (Gibco Cat. No. 15140122).

Unless otherwise indicated, adherent cells are passaged using trypsin-EDTA (0.05%, Gibco Cat. No. 25300054). Some lines require 0.25% trypsin/1mM EDTA without Ca²⁺ Mg²⁺ (EMD Millipore, Cat. No. SM-2003-C), or this buffer diluted to 0.2% trypsin.

Cells transfected with plasmid are maintained with **blasticidin** (Thermo Fischer Scientific, Cat. No. A1113903) or **puromycin** (Sigma Aldrich, Cat. No. P9620-10ML).

Lung

- 3 Non-small cell lung cancers:

Lung adenocarcinomas:

1. A549 (RRID:CVCL_0023) was purchased from the American Type Culture Collection (ATCC) in March 2019; grown in R10 and split 1/20 twice per week.
2. NCI-H322 (RRID:CVCL_1556; purchased May 2019, Sigma Aldrich) grown in R10 and split 1/3 to 1/6 twice per week.
3. NCI-H522 (RRID: CVCL_1567) grown in R10 and split 1/3 to 1/6 twice per week.

Large cell lung carcinoma:

1. NCI-H460 (RRID:CVCL_0459; purchased June 2019, ATCC) grown in R10 and split 1/8 three times per week.

Prostate

- 4 Castration resistant prostate cancer (CRPC):
1. LnCAP (RRID: CVCL_0395) grown in R10, harvest with 0.2% trypsin.

Mesothelioma

- 5 Pleural epithelioid mesothelioma:
1. NCI-H2452 (RRID:CVCL_1553)
 2. NCI-H226 (RRID:CVCL_1544) obtained by Dan Vallera's lab in 2009.
 3. NCI-H2461(RRID:CVCL_A536) grown in R10 and split 1/20 twice per week.
 4. YOU (RRID:CVCL_N819; Gift of Raffit Hassan, 2021, see Li et al. <http://www.ncbi.nlm.nih.gov/pubmed/15274292>) grown in R10 and split 1/4 twice a week.
 5. HAY (RRID:CVCL_N813; Gift of Raffit Hassan, 2021, see Li et al. <http://www.ncbi.nlm.nih.gov/pubmed/15274292>) grown in R10 and split 1/4 twice per week.
 - 5A. HAY-luciferase/GFP created by Blake Jacobson, Manish Patel's lab, 2021) grown in R10 with 2µg/mL blasticidin for selection of the GFP/luciferase.
 6. ORT (RRID:CVCL_N815; Gift of Raffit Hassan, 2021, see Li et al. <http://www.ncbi.nlm.nih.gov/pubmed/15274292>) grown in R10 and split 1/2 twice per week.
 7. ROB (RRID:CVCL_N818; Gift of Raffit Hassan, 2021, see Li et al. <http://www.ncbi.nlm.nih.gov/pubmed/15274292>) grown in R10 and split 1/4 twice per week.
 8. PET (RRID:CVCL_N816; Gift of Raffit Hassan, 2021, see Li et al. <http://www.ncbi.nlm.nih.gov/pubmed/15274292>) grown in R10 and split 1/2 twice per week.

Sarcomatoid mesothelioma:

1. NCI-H2596(RRID:CVCL_A546) grown in R10 and split 1/20 twice per week.
2. NCI-H2691(RRID:CVCL_A551)
3. NCI-H2373(RRID:CVCL_A533) grown in R10 and split 1/5 twice per week.

Leukemia

- 6 Chronic myelogenous leukemia
1. K562 (RRID:CVCL_0004; purchased March 2015, Cat. No. CCL-243, ATCC) cultured in R10, split down to 1×10^5 cells/mL three times per week.
 - 1A. K562-Nuclight Red (Gift of Fate Therapeutics, created using Incucyte Nuclight Red Lentivirus Reagent, EF1a, Puro; Sartorius, Cat. No. 4625) expression maintained with 1µg/mL puromycin.
- Acute myeloid leukemia
1. HL-60 (RRID:CVCL_0002; purchased from April 2017, Cat. No. CCL-240, ATCC) grown in R10, split down to 2×10^5 cells/mL two to three times per week.

Childhood acute monocytic leukemia

1. THP-1 (RRID:CVCL_0006; purchased December 2015, Cat. No. TIB-202, ATCC) cultured in R10 with 50µM β-mercaptoethanol. Split down to 2-4x10⁵ cells/mL. Subculture when cell concentration reaches 8x10⁵ cells/mL. Do not allow the cell concentration to exceed 1x10⁶ cells/mL.
2. MV-4-11 (RRID:CVCL_0064; purchased February 2015, Cat. No. CRL-9591, ATCC)

Plasma cell myeloma

1. MM1.S (RRID:CVCL_8792; purchased December 2021, Cat. No. CRL-2974, ATCC) cultured in R10. Scrape to split 1/2 twice or three times per week. Spin at 125g 5min.

Breast

- 7 Breast adenocarcinoma:
 1. MDA-MB-231 (RRID: CVCL_0062) - triple negative breast cancer

Lymphoma

- 8 Epstein-Barr virus-related Burkitt lymphoma
 1. Raji (RRID:CVCL_0511; purchased March 2015, Cat. No. CCL-86, ATCC) cultured in R10, split down to 4 x10⁵ cells/mL three times per week.
 - 1A. Raji-Nuclight Red (Gift of Fate Therapeutics, created using Incucyte Nuclight Red Lentivirus Reagent, EF1a, Puro; Sartorius, Cat. No. 4625) expression maintained with 1µg/mL puromycin.
 2. Daudi (RRID:CVCL_0008; purchased April 2018, Cat. No. CCL-213, ATCC) cultured in R10, split down to 3-5x10⁵ cells/mL; should not exceed 3x10⁶ cells/mL.

Gut

- 9 Colon adenocarcinoma
 1. CaCO-2 (RRID: CVCL_0025) purchased from ATCC before 2016 (Schohl et al. Targeted Oncology, 2016, doi:10.1007/s11523-015-0391-8)
Cultured in Eagle's Minimum Essential Medium (ATCC Cat. No. 30-2003) + 20% fetal bovine serum (Gibco Cat. No. 26140079) + 100 U/mL Penicillin and Streptomycin (Gibco Cat. No. 15140122); split 1/2 once per week.
 2. HT29 (RRID:CVCL_0320; purchase May 2022, Cat. HTB-38, ATCC)
P0 to P2 were cultured in McCoy's 5A medium modified (30-2007, ATCC); P3 onwards grown in R10. All split 1/8 3 times per week, down to 40,000 cells/cm².
 - 2A. HT29-Nuclight Red (Gift of Daniel Vallera, 2022) expression maintained in 0.5µg/mL puromycin.

2B. HT29-GFP/luciferase (Gift of Daniel Vallera, 2022) expression maintained in 10µg/mL blasticidin.

Endometrium

- 10 Endometrial adenocarcinoma
1. Ishikawa 3-H-12 (same as ECC-1) sensitive
 2. Ishikawa 3-H-12 (same as ECC-1) resistant

Head and Neck

- 11 Human papilloma virus-negative Head and Neck Squamous Cell Carcinomas (HNSCCs):
1. Cal27 (RRID:CVCL_1107; Gift of Garcia-Escudero lab, Spain, received in 2021) cultured in 15 mL D10/T75, split 3 times a week at 0.1 mil. cells/ mL, harvested using 0.25% trypsin (3 mL for T75, 5 mL for T150) for 3.5 minutes.
1A. Cal27-Nuclight Red (generated by Melissa Khaw, using Incucyte Nuclight Red Lentivirus Reagent, EF1a, Puro; Sartorius, Cat. No. 4625, August 2021), puromycin selection at 1.5 ug/ mL.
 2. Cal33 (RRID:CVCL_1108; Gift of Garcia-Escudero lab, Spain, received in 2021) cultured in 15mL D10/T75, split 3 times a week at 0.1 mil. cells/ mL, harvested using 0.25% trypsin (3 mL for T75, 5 mL for T150) for 3.5 minutes.
2A. Cal33-Nuclight Red (generated by Melissa Khaw, using Incucyte Nuclight Red Lentivirus Reagent, EF1a, Puro; Sartorius, Cat. No. 4625, August 2021), puromycin selection at 1.5 ug/ mL.

NK cell lines

- 12 Malignant non-Hodgkin's lymphoma
1. NK-92 (RRID:CVCL_2142; Gift of Kerry Campbell, Philadelphia, 2018)
(see also *Assessing IL-15 bioavailability - 'the bioassay'*) NK-92 are maintained in Alpha Minimum Essential Medium plus ribonucleosides and deoxyribonucleosides (12571, Gibco), β-mercaptoethanol (0.1mM, M7522, Sigma Aldrich), recombinant human IL-2 (100U/mL, NDC 65483-116-07, Prometheus), horse serum (12.5%, 26050088, Fisher Scientific), fetal bovine serum (12.5%, 26140079, Gibco), Penicillin and Streptomycin (100U/ml, 15140122, Gibco). Split down to 2×10^5 - 3×10^5 cells/mL three times per week.
NK-92 freezing medium: 50% FBS; 40% NK92 media; 10% DMSO. Freeze no more than 5×10^6 cells/mL

T cell lines

- 13 Childhood T lymphoblastic leukemia
1. Jurkat clone E6.1 (RRID:CVCL_0367; purchased June 2015, Cat No. TIB-152, ATCC)

Miscellaneous

- 14** Mouse mast cell neoplasm
1. P815 (ATCC Cat. No. TIB-64, purchased August 2017, RRID:CVCL_2154) cultured in D10; split down to 1×10^5 cells/mL three times per week.
- 15** Human Dermal Microvascular Endothelial Cells
1. HDMEC (Sigma Aldrich Cat. No. S100-05A)
Human Microvascular Endothelial Cells - Lung
1. HMVEC-L (Lonza Cat. No. CC-2527)
- 16** Renal clear cell carcinoma
1. Caki-1 (RRID:CVCL_0234; purchased July 2018, Cat. No. HTB-46, ATCC)
2. Caki-2 (RRID:CVCL_0235; purchased March 2020, Cat. No. HTB-47, ATCC)
- 17** Mouse fibroblast
1. L cells (RRID:CVCL_4536; purchased February 2016, Cat. No. CRL-2648, ATCC)
- 18** Osteosarcoma
1. U2OS (RRID:CVCL_0042; purchased March 2020, Cat. No. HTB-96, ATCC)
Note - you cannot treat this cell line effectively with mycoplasma removal agent (Cat. No. BUF035, BioRad)